เอกสารการประชุมวิชาการและเสนอผลงานวิจัย มหาวิทยาลัยทักษิณ ครั้งที่ 19 2552 - page 806

„µ¦ž¦³»¤ª·µ„µ¦Â¨³Áœ°Ÿ¨Šµœª·‹´¥¤®µª·š¥µ¨´¥š´ „¬·– ‡¦´Ê Šš¸É 19 ž¦³‹Îµže 2552
3
Enteroinvasive E. coli (EIEC) Enterohaemorrhagic E. coli (EHEC) ¨³ Enteroaggregative E. coli (EAEC)
(» ¬„¦ °»˜¦£·µ˜·, 2547)
„¦¤ª·š¥µ«µ˜¦r„µ¦Â¡š¥r (2536) ŗo „ε®œ—Á„–”r¤µ˜¦“µœšµŠ‹»¨¸ªª· š¥µ °Š°µ®µ¦ž¦³Á£š˜nµŠÇ
Ánœ °µ®µ¦ž¦»Š»„š´ÉªÅž °œ» µ˜Ä®o¡ž¦·¤µ–‹»¨·œš¦¸¥rš´Ê Š®¤—Å—oœo°¥„ªnµ 1 x 106 CFU/g ž¦· ¤µ–Ǩ·¢°¦r¤ ¨³
E.coli œo°¥„ªnµ 500 ¨³ œo°¥„ªnµ 3 MPN/g ˜µ¤¨Îµ—´ Î µ®¦´£µœ³´¤Ÿ´ °µ®µ¦(°»ž„¦–rĜ„µ¦¦· ㇰµ®µ¦
ŗo „n ‹µœ µ¤ o°œ „oªœÊε Áž}œ˜oœ) °œ»µ˜Ä®o¡‹» ¨·œš¦¸¥rš´ÊŠ®¤—Äœž¦·¤µ–œo°¥„ªnµ 1 x 103 CFU /£µœ³
1 ·Ê œ Áž}œ˜oœ
ÁœºÉ °Š‹µ„¥´ ŠÅ¤n ¤¸o °¤¼¨„µ¦˜¦ª‹‡» –£µ¡šµŠ‹»¨¸ªª· š¥µ °Š¢°ŠœÊÎ µ¨oµŠ‹µœ °Š¦o µœ°µ®µ¦˜n µŠÇ
Ĝ¤®µª· š¥µ¨´¥š´„¬· – ª· š¥µÁ ˜Š ¨µ Ž¹ÉŠÂ˜n¨³ª´ œ¤¸œ· · ˜Â¨³»‡¨µ„¦ ¦ª¤š´ÊŠ»‡‡¨£µ¥œ°„‹Îµœªœ¤µ„
¦´ ž¦³šµœ°µ®µ¦Â¨³Á‡¦ºÉ °Š—ºÉ¤ —´ Šœ´Êœ„µ¦«¹ „¬µœ¸Ê ‹¹ Š¤¸‡ªµ¤œÄ‹š¸ ɋ³˜¦ª‹®µ‡» –£µ¡šµŠ‹» ¨¸ªª· š¥µ
°Š¢°ŠœÊε¨oµŠ‹µœ ˜nÁœºÉ°Š‹µ„„µ¦˜¦ª‹®µÁºÊ °Ã¦‡šµŠÁ—·œ°µ®µ¦¤¸ª·›¸„µ¦¥»n Š¥µ„„ªnµ„µ¦˜¦ª‹®µÃ‡¨·¢°¦r¤Â¨³
E. coli Ž¹ÉŠÁž}œ‹»¨·œš¦¸ ¥rž¦³‹Îµ™·ÉœÄœ¨ÎµÅo °Š´ ˜ªrÁ¨º°—°»nœ ¨³Áž}œÁºÊ°—´ œ¸ nŠ¸Ê „µ¦žœÁžg°œ °Š°» ‹‹µ¦³
o°¤¼¨‹µ„„µ¦«¹„¬µ ‹³œÎµÅžÄož¦´ž¦»Š‡» –£µ¡ °Š„µ¦¨oµŠ‹µœÄ®o—¸¹Êœ Ž¹É Š‹³Áž}œž¦³Ã¥œr°¥nµŠ¥·ÉŠ˜n°‡» –£µ¡
¸ª·˜ °Šœ· ·˜Â¨³»‡¨µ„¦ °Š¤®µª·š¥µ¨´¥ ¦ª¤š´ÊŠ»‡‡¨£µ¥œ°„š¸ÉÁ oµ¤µ¦´ž¦³šµœ°µ®µ¦ÄœÃ¦Š°µ®µ¦°¸„—oª¥
ª´˜™» ž¦³Š‡r
1.Á¡ºÉ°˜¦ª‹®µž¦·¤µ–‡š¸Á¦¸¥š´ÊŠ®¤— ž¦·¤µ–Ǩ·¢°¦r¤ ¨³ E. coli Ĝ¢°ŠœÊε¨oµŠ‹µœ
2. Á¡ºÉ°œÎµ o°¤¼¨š¸Éŗo ‹oŠ‡–³„¦¦¤„µ¦‡ª‡»¤¦oµœ°µ®µ¦Â¨³Á‡¦ºÉ°Š—ºÉ¤ °Š¤®µª·š¥µ¨´ ¥š´„¬·– Á¡ºÉ°Äo
Áž}œÂœªšµŠÄœ„µ¦ž¦´ž¦»Š‡»–£µ¡„µ¦¨oµŠ‹µœÄœÃ¦Š°µ®µ¦ °Š¤®µª·š¥µ¨´¥˜n°Åž
°»ž„¦–r¨³ª·›¸„µ¦
°»ž„¦–r
°µ®µ¦Á¨¸Ê ¥ŠÁºÊ° : Brilliant Green Lactose Bile Broth (BGLB); Eosin Methylene Blue (EMB) Agar
Escherichia coli (EC) Medium; Lauryl Sulfate Broth (LSB)
Methyl Red – Voges Proskauer (MR-VP) Broth; Nutrient Agar (NA)
Plate Count Agar (PCA); Simmon,s Citrate Agar ; Tryptone Broth
µ¦Á‡¤¸ : Phosphate Buffer Solution (PBS) »—¸¥o°¤Â„¦¤ Á°š›µœ°¨ ¨³ œÊε¥µÁÈ—Øp³ Áž}œ˜oœ
Á‡¦ºÉ°ŠÂ„oª : ª—°µ®µ¦ ‹µœÁ¡µ³ÁºÊ° ¸„Á„°¦r ždÁž˜ Ũ—r ®¨°—š—¨°Š ¨³ ®¨°——´„„p
Á‡¦ºÉ°Š¤º° ¨³°»ž„¦–r°ºÉ œÇ : „¨o°Š‹»¨š¦¦«œr ®¤o °œ¹ÉŠ‡ªµ¤—´ œ ˜¼o°‡ªµ¤¦o°œ °nµŠœÊ凪‡» ¤°»–®£¼¤·
˜¼on ¤ÁºÊ° ˜³Á„¸ ¥ŠÂ°¨„°±°¨r ®nªŠÁ ¸É¥ÁºÊ° Áž} œ˜oœ
ª·›¸„µ¦
čoÁš‡œ·‡ž¨°—ÁºÊ°Á„È ˜´ª°¥nµŠ¢°ŠœÊε‹µ„¦oµœ°µ®µ¦ ‹Îµœªœ 13 ¦oµœ ˜n¨³¦oµœÁ„È ˜´ª°¥nµŠ 3 ‡¦´ÊŠ
˜n¨³‡¦´ÊŠ®nµŠ„´œ 1 Á—º°œ ¦ª¤ 39 ˜´ ª°¥nµŠ œÎµÅž˜¦ª‹ª· Á‡¦µ³®r‹»¨·œš¦¸¥r—´Šœ¸Ê
1. „µ¦˜¦ª‹œ´ ž¦·¤µ–‹»¨·œš¦¸¥rš´Ê Š®¤— čoª·›¸ „µ¦Á¡µ³ÁºÊ°Äœ‹µœ°µ®µ¦ PCA (Peter, Weagant and
Grant, 2002) ×¥´ÉŠ˜´ª°¥n µŠ¢°ŠœÊ宜´„ 50 „¦´¤ ÄnĜµ¦¨³¨µ¥ PBS 450 ¤· ¨¨·¨·˜¦ ‹³Å—o ‡ªµ¤Á‹º°‹µŠ 10-1 ¨³